Diabetic nephropathy

Nikolas B. Harbord, James F. Winchester, Elliot Charen, Chiarra Ornillo, Naitik Sheth, Donald Feinfeld, Alan Dubrow

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations

Abstract

Diabetes is the most common cause of end-stage kidney disease in the world. Diabetic nephropathy is due to cellular and subcellular mechanisms and involves induction of signaling pathways in the kidney which perpetuate the destruction of glomeruli, the intrarenal vasculature, and the interstitium. Diagnosis and prevention center on the detection of albuminuria, tight plasma glucose control, as well as primary interruption of the renin-angiotensin- aldosterone system, which reduces the transglomerular hydrostatic pressure. Some of the newer glucose control therapeutic agents have shown benefit in diabetic nephropathy, and the future holds promise for specific inhibitors of inflammation, as well as inhibitors of microRNA species. Comorbid conditions such as large vessel disease are also commonly associated and require vigilance on the part of the physician and those supervising the predialysis and dialysis patients.

Original languageEnglish
Title of host publicationPrinciples of Diabetes Mellitus
Subtitle of host publicationThird Edition
PublisherSpringer International Publishing
Pages425-442
Number of pages18
ISBN (Electronic)9783319187419
ISBN (Print)9783319187402
DOIs
StatePublished - 7 Jul 2017

Keywords

  • Genetics
  • Inflammation
  • Microrna
  • Nephropathy
  • Novel therapy
  • Renin-angiotensin

Fingerprint

Dive into the research topics of 'Diabetic nephropathy'. Together they form a unique fingerprint.

Cite this